A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)

被引：0

作者：

Ross, Ashley

Armstrong, Andrew J.

Pieczonka, Christopher M.

Bailen, James L.

Tutrone, Ronald F.

Cooperberg, Matthew R.

Pavlovich, Christian P.

Renzulli, Joseph F.

Haynes, Heather

Sheikh, Nadeem Anwar

Shore, Neal D.

机构：

[1] Mary Crowley Canc Res, Dallas, TX USA

[2] Duke Canc Inst, Durham, NC USA

[3] Associated Med Profess New York PLLC, Syracuse, NY USA

[4] First Urol Res, Louisville, KY USA

[5] Chesapeake Urol, Towson, MD USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Johns Hopkins Med Inst, Baltimore, MD 21205 USA

[8] Yale Sch Med, Providence, RI USA

[9] Dendreon Pharmaceut LLC, Seattle, WA USA

[10] Carolina Urol Res Ctr, Myrtle Beach, SC USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

321

引用

页数：2